100 % Santé audiology: hearing aid price and reimbursement in 2026

Quick answer. In 2026, the 100 % Santé audiology scheme lets a patient obtain a Class I hearing aid with no out-of-pocket cost. For an adult, the price limit is 950 € incl. VAT per ear, social security reimburses 240 € and the responsible complementary insurer covers the balance. Final out-of-pocket cost: 0 €. Cover can only be renewed after 4 years, per ear.

Selling a hearing aid with zero out-of-pocket cost looks simple from the patient's side. From a hearing centre's management side, it is another story: a capped selling price, two payers (social security and the complementary insurer) settling with a lag, and third-party payment receivables to track item by item. This twofold reality, a framed price for the patient and fragmented cash flow for the professional, deserves to be set out clearly before opening or steering a centre.

We restate the 2026 schedule here, what the scheme actually covers, then the angle that occupies us day to day: what 100 % Santé changes for a hearing care professional's accounting and cash flow.

The scheme rests on two equipment families listed on the schedule of reimbursable products and services (LPP), within the meaning of article L165-1 of the French Social Security Code.

• Class I is capped by a price limit (PLV). Combined with a responsible complementary insurance contract, it produces a zero out-of-pocket cost.
• Class II has a free price. Its remaining cost depends on the guarantees taken out in the patient's insurer contract.

The hearing care professional has one simple obligation to remember: every quote must include at least one Class I equipment with zero out-of-pocket cost. The patient then chooses in full knowledge, without being steered by default toward a paid option. This rule shapes the commercial relationship as much as the centre's compliance.

For an insured person over 20, the Class I equipment is capped at 950 € incl. VAT per ear. The social security reimbursement base (BRSS) is 400 €. The health insurance fund reimburses 60 % of that base, i.e. 240 €. The responsible complementary insurer covers the remainder to reach a 0 € out-of-pocket cost.

For an appliance fitted on both ears, these amounts are counted per ear: the price limit, the base and the reimbursement apply device by device. A bilateral fitting for an adult therefore represents 1,900 € incl. VAT in cumulative price limit, 480 € of social security share and the balance borne by the insurer.

For those under 20, and for people affected by blindness, the cover is markedly more favourable. The price limit of a Class I equipment rises to 1,400 € incl. VAT per ear, and the reimbursement base is also 1,400 €. Social security reimburses 60 % of 1,400 €, i.e. 840 €, with the responsible insurer covering the balance for a 0 € out-of-pocket cost.

The table below sums up both schedules, per ear and for Class I.

Two gaps stand out. First, the price limit is higher for young patients, which leaves more pricing room. Second, and above all, the reimbursement base fully matches the price limit for the under-20s, where it stops at 400 € for adults: the social security share therefore covers a far larger fraction of the price, and reliance on the insurer is lower.

Zero out-of-pocket cost is not limited to the device. The cover includes follow-up, adjustments and maintenance of the hearing aid over its whole lifespan. An important planning point for both patient and centre: cover can only be renewed after a period of 4 years, per ear.

What Class I actually covers, to check on the quote:

• at least one Class I equipment offered on every quote;
• price limit respected (950 € adult, 1,400 € under 20);
• follow-up, adjustments and maintenance included in the service;
• cover renewal possible after 4 years, per ear;
• zero out-of-pocket cost under a responsible contract.

This logic of an overall service, rather than a simple product sale, has a direct accounting translation. The price collected pays for several years of support: margin cannot be read at the point of sale alone, but over the duration of the patient journey.

Behind the zero out-of-pocket cost for the patient, the cash-flow mechanics of a hearing centre are less simple. These amounts pass through third-party payment: the social security share and the insurer share are collected with a lag, which creates receivables to track item by item. A rejected or pending insurer share is cash tied up for several weeks.

The margin on Class I is also capped by the price limit. Steering therefore plays out on three levers: the Class I / Class II mix, the actual collection time for both shares, and the rigorous tracking of teletransmission rejections.

Quick decision: which management point to watch first?#

1. Do not confuse revenue with cash. An invoiced sale is not a collected sale until both shares are settled. The third-party payment lag can widen the working capital need, especially during growth.
2. Track teletransmission rejections one by one. An untreated rejection is a dormant receivable. The rejection rate and the chasing time deserve a dedicated indicator.
3. Read net margin after the PLV. On Class I, the price is capped: profitability plays out on purchase costs and time spent on follow-up, not on the selling price.
4. Anticipate the 4-year renewal. The fitting frequency per patient shapes recurring revenue; it can be steered, not merely endured.

Hayot Expertise tip. Build a dashboard that separates the social security share from the insurer share, payer by payer, and shows the average collection time for each. It is this twofold tracking, not the total invoiced, that reveals a hearing centre's true financial health.

In the hearing-centre files we support, the most frequent frictions do not concern the device sold, but the recovery of the complementary share and the reading of net margin once the PLV is factored in. A centre can show rising revenue while squeezing its cash flow, simply because insurer shares are slow to arrive.

We once reviewed the management of a centre whose growth masked a rising working capital need: the owner was steering by revenue, without distinguishing what had been collected from what was still awaiting third-party payment. By isolating receivables by payer and setting up rejection tracking, the "cash tied up" item became readable, and chasing could be prioritised. The diagnosis was not accounting in the technical sense: it stemmed from the very structure of payment in this profession, which few standard dashboards reflect.

Our conviction: in audiology, the right indicator is not the gross margin shown at the sale, but the pairing of net margin after PLV and actual collection time per payer. That is where lasting profitability is decided.

To structure this tracking and build a dashboard suited to third-party payment, our firm supports hearing care professionals: see our dedicated page on the chartered accountant for hearing care professionals, which details the accounting, tax and steering issues specific to the sector. If you are planning to set up, our guide on opening a hearing-care practice and the audiologist's status usefully complements these management benchmarks. For the tax and filing side, we also act through our tax chartered accountant in Paris and our chartered accountancy firm in Paris 8.

This article informs on the 2026 framework; a decision specific to your situation requires reviewing your contracts, your figures and the rules in force.